BioNTech mRNA manufacturing facility opens

The trace

How it reaches your house.

Starting from Aldevron, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.

1. First impact

   Sartorius Stedim Biotech →Prices rise

   Single-Use Bioreactor Bags (Cellbag)

   BioNTech's new facility should lift biomanufacturing activity and demand for Sartorius's single-use bioreactor bags; with 28% market share and a 10-month replacement lead time, the input's pricing pressure should rise moderately.

   57% confidence

   Aldevron →Prices rise

   mRNA Cap Analogs (CleanCap, co-transcriptional)

   BioNTech's new clinical-scale mRNA manufacturing facility should lift demand for mRNA cap analog inputs like CleanCap, modestly tightening a market where Aldevron has an 8% share and substitution is limited.

   55% confidence

2. Hop 2

   Single-Use Bioreactor Bags (Cellbag) →Stands to benefit

   Sartorius AGSRT

   BioNTech's added mRNA capacity should lift demand for Cellbag bags, benefiting Sartorius's largest-share supplier relationship.

   82% confidence

   Single-Use Bioreactor Bags (Cellbag) →Stands to benefit

   Thermo Fisher ScientificTMO

   A new vaccine/biologics facility should increase orders for bioprocessing consumables like Cellbag bags, benefiting this major supplier.

   80% confidence

   Single-Use Bioreactor Bags (Cellbag) →Stands to benefit

   Sartorius Stedim Biotech

3. Hop 3

   Merck KGaA Life Science (MilliporeSigma) →Stands to benefit

   Lipid nanoparticle (LNP) lipid components

   BioNTech's added mRNA capacity should directly raise demand for LNP lipids used in mRNA formulation, benefiting this input line.

   83% confidence

   Merck KGaA Life Science (MilliporeSigma) →Stands to benefit

   Sterile filtration membrane (0.2 μm)

   More vaccine and biologics output should increase usage of sterile filtration membranes in downstream processing, lifting demand for this product.

   80% confidence

   Merck KGaA Life Science (MilliporeSigma) →Stands to benefit

   Bioprocess Ultrafiltration Membranes

4. Hop 4

   N1-Methylpseudouridine (m1Ψ-UTP) — mRNA Immune Evasion →supply up

   Vaccines

   BioNTech's added mRNA manufacturing capacity directly raises vaccine output, and m1Ψ-UTP is a critical input to that production.

   82% confidence

   Lipid nanoparticle (LNP) lipid components →Stands to benefit

   Merck KGaA Life Science (MilliporeSigma)MRK.DE

   BioNTech's added mRNA output should raise demand for LNP lipid components, and Merck's 30% supply share means it captures a substantial portion of that incremental demand.

   78% confidence

   0.22-μm Sterilizing-grade Membrane Filters (PVDF/PTFE/PES) →Stands to benefit

   Merck KGaA (MilliporeSigma / SAFC Biosciences)